At a glance
ClinicalIndex Comparison RecordPhase 1Completed· 17 enrolled
Drug / intervention
Open Label LAM-003drug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase 1 Dose-Escalation Study of LAM-003 in Patients With Acute Myeloid Leukemia
In Brief
A Phase 1 clinical trial evaluating Open Label LAM-003 for Oncology and Acute Myeloid Leukemia. Completed, enrolled 17 participants across 6 sites.
Detailed Summary
A Phase 1 Dose-Escalation Study of LAM-003 in Patients with Acute Myeloid Leukemia
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsOncology, Acute Myeloid Leukemia
CountriesUnited States
Collaborators--
Timeline
Phase 1CompletedFinished
201820192020202120222023202420252026
Enrollment StartJan 2018
First PostedFeb 2018
Primary CompletionFeb 2020
Study CompletionOct 2020
TodayJul 2026
First PostedFeb 8, 2018
Enrollment StartJan 16, 2018
Primary CompletionFeb 20, 2020
Study CompletionOct 5, 2020
TodayJul 2, 2026
Enrollment to primary: 2.1 yearsPosted 8.4 years ago
Interventions
Open Label LAM-003drug
LAM-003